Starting a Discussion thread on listed UK biotech to explore where the opportunities lie....
This FT article confirms that funding is thin on the ground - http://www.ft.com/cms/s/0/7dac700c-1c8f-11de-977c-00144feabdc0.html - with a number of companies, including AIM listed Ardana, hitting the wall, while Stem Cell Sciences has been sold to a US rival and at at least two others – Intercytex and Summit – "have cut staff numbers and are considering a partial or full sale in order to survive".
Are there any diamonds in the rough?
